Published: May 16, 2026 · Last updated: May 16, 2026
- Roughly 50 to 60% of postmenopausal women experience symptoms of genitourinary syndrome of menopause (GSM), including vaginal dryness, painful sex, and recurrent urinary tract infections (Mayo Clinic, 2024)
- Local vaginal estrogen has a strong safety profile, with minimal systemic absorption, and is appropriate for many women who cannot or chose not to use systemic hormone therapy (Cleveland Clinic, 2024)
- DHEA suppositories (prasterone) and the prescription oral medication ospemifene are non-estrogen alternatives with comparable efficacy for many women (Mayo Clinic, 2024)
The conversation with the doctor lasts 60 seconds. You bring up the dryness, the discomfort during sex, maybe the urinary tract infections that keep recurring. You get handed a tube of over-the-counter lubricant and a vague suggestion to "use it more often." You go home. The lubricant helps with the friction at the surface but does not touch the underlying problem. Three months later, nothing has improved, and you assume this is just what life looks like now.
This is the most common and most undertreated cluster of symptoms in postmenopausal women's health. The name has evolved from the older "vaginal atrophy" to the more accurate "genitourinary syndrome of menopause" (GSM), reflecting that the same hormonal changes affect the vagina, vulva, urethra, and bladder together. The treatment options have also evolved well beyond drugstore lubricant. Women are simply not being told.
What Is Actually Happening Biologically
Estrogen receptors are densely concentrated in vaginal, vulvar, and urethral tissue. When estrogen levels fall after menopause, those tissues thin, lose elasticity, produce less natural lubrication, and shift to a less acidic pH. The result is a cascade: dryness, friction, painful intercourse, microscopic tears that can bleed, increased susceptibility to UTIs because of pH change, and over time, vulvar architecture changes that make the entrance to the vagina narrower and more rigid.
None of this is "just aging." It is a specific, treatable, hormonal-tissue process. And unlike hot flashes, which often improve over time, GSM symptoms progress without treatment. The longer the wait to treat, the harder it is to fully reverse (Mayo Clinic, 2024).
Why Lubricant Alone Falls Short
Over-the-counter lubricants reduce friction during sex. They are useful as a complement to other treatment, but they do not address tissue thinning, the pH shift, or the susceptibility to UTIs. Vaginal moisturizers (a different category, used every few days regardless of sexual activity) help more because they restore some water content to the tissues. The two are often confused at the drugstore.
For mild symptoms in someone who is otherwise comfortable, moisturizers like Replens or hyaluronic-acid-based products may be sufficient. For most women with meaningful GSM, the medical treatments below produce dramatically better results.
Local Vaginal Estrogen: The Treatment Most Women Are Not Told About
Local vaginal estrogen comes as a cream (Premarin, Estrace), a small tablet inserted into the vagina (Vagifem), or a low-dose ring placed in the vagina and changed every 90 days (Estring). Doses are tiny compared to systemic hormone therapy: typically about 1/50th to 1/200th the dose of estrogen used in oral HRT. Systemic absorption is minimal, with blood estrogen levels remaining in the postmenopausal range in most users.
Effectiveness is high. Most women see meaningful symptom improvement within 4 to 8 weeks, with full benefit by 12 weeks. The treatment is generally continued indefinitely, because stopping it allows the tissue changes to recur. Safety data, including from women with a history of estrogen-sensitive cancers in some specific circumstances, are reassuring; the North American Menopause Society and the American College of Obstetricians and Gynecologists both endorse local vaginal estrogen as a first-line treatment for GSM (Mayo Clinic, 2024).
Non-Estrogen Alternatives
For women who prefer to avoid any estrogen exposure or who have specific contraindications, two strong alternatives exist. DHEA suppositories (prasterone, brand name Intrarosa) are inserted nightly. The DHEA is converted locally to estrogen and testosterone within the vaginal tissues, providing the benefits with minimal systemic absorption.
Ospemifene (Osphena) is an oral SERM (selective estrogen receptor modulator) that acts as an estrogen agonist in vaginal tissue but not in breast or uterine tissue. Taken daily as a pill, it is particularly useful for women who prefer not to use vaginal preparations. Both options are evidence-based and FDA-approved for moderate-to-severe symptoms of GSM (Cleveland Clinic, 2024).
What Pelvic Floor PT Adds
Many women with longstanding GSM also develop pelvic floor muscle tension as a guarding response to painful sex. The body learns to brace, which makes intercourse more uncomfortable, which reinforces the bracing. Local estrogen addresses the tissue side; pelvic floor PT addresses the muscle side. The combination often works better than either alone.
Pelvic floor PT specifically for GSM-related pelvic pain typically runs 8 to 12 weeks. The therapist works on muscle release techniques, breath integration, and gradual desensitization with dilators if needed. Many women describe the combination of local estrogen plus PT as transformational, restoring not just function but quality of life.
To your health,
Ageless Coach
Age Strong. Live Long.
Trusted Sources Behind This Article
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Reading this article does not create a provider-patient relationship. Always consult your physician or qualified healthcare provider before making changes to your diet, exercise, or health routine. Ageless Coach is not liable for any actions taken based on this information.
Frequently Asked Questions
Want one verified-science article like this every week?
Get Better Health, Weekly